Research map: Time-dependent bias in local consolidative therapy for EGFR-mutant metastatic non-small cell lung cancer

Back to the article

Papers in this map

  1. Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer · Jean‐Charles Soria · 2017 · 5482 citations · Cited by this paper
  2. Epiproteomic profiling identifies histone H4 hyperacetylation as a prognostic marker in pleural mesothelioma · 2026 · Related
  3. Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studies · Peter C. Austin · 2010 · 4067 citations · Cited by this paper
  4. Neoadjuvant and perioperative chemo-immunotherapy in early-stage non-small cell lung cancer: international expert panel meeting by AIOT · 2026 · Related
  5. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial · David A. Palma · 2019 · 1895 citations · Cited by this paper
  6. BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer · 2026 · Related
  7. Immortal Time Bias in Pharmacoepidemiology · Samy Suissa · 2007 · 1793 citations · Cited by this paper
  8. Real-world burden of cardiovascular events following immune checkpoint inhibitor therapy: impact on mortality and treatment resumption in 29,503 patients · 2026 · Related
  9. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study · Daniel Richard Gomez · 2016 · 1104 citations · Cited by this paper
  10. Biology, detection, and management of incidental pulmonary nodules: the emerging role of targeted treatments. A review of the current literature and future perspectives · 2026 · Related
  11. Understanding and targeting resistance mechanisms in NSCLC · Julia K. Rotow · 2017 · 1040 citations · Cited by this paper
  12. Efficacy and safety of immune checkpoint inhibitors in lung cancer patients with hepatitis B surface antigen positivity: a real-world cohort study · 2026 · Related
  13. Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer · Xiaoshan Wang · 2022 · 271 citations · Cited by this paper
  14. Clonal divergence with acquired BRAF V600E in NSCLC with compound EGFR G719X/S768I after prolonged EGFR-TKI therapy · 2026 · Related
  15. Osimertinib, Surgery, and Radiation Therapy in Treating Patients with Stage IIIB or IV Non-Small Cell Lung Cancer with EGFR Mutations (NORTHSTAR) · Tahsin M. Khan · 2022 · 34 citations · Cited by this paper
  16. CT surveillance, patterns of recurrence and eligibility for salvage therapy after curative intent treatment for unresectable stage III non small cell lung cancer · 2026 · Related
  17. LBA72 NorthStar: A phase II randomized study of osimertinib (OSI) with or without local consolidative therapy (LCT) for metastatic EGFR-mutant non-small cell lung cancer (NSCLC) · Y.Y. Elamin · 2025 · 16 citations · Cited by this paper
  18. First-line treatment for unresectable pulmonary lymphoepithelial carcinoma: A real-world comparison of platinum-based doublet chemotherapy with or without PD-1 inhibitors · 2026 · Related
  19. To ablate or not to ablate? Outcomes of local ablative treatments (LAT) for oncogene addicted (OA) oligo-metastatic (OM) non-small cell lung cancer (NSCLC): A systematic review · Fabrizio Citarella · 2025 · 2 citations · Cited by this paper
  20. Development and validation of a risk-stratification model for individualized management of leptomeningeal metastases in EGFR- mutant NSCLC (LM-Index) · 2026 · Related
  21. The Effects of Variant Allele Frequency for EGFR Mutation on Early Tumor Shrinkage and Deepness of Response to Osimertinib in Patients with Metastatic Non-Small Cell Lung Cancer: An Exploratory Analysis · Giuseppe Bronte · 2026 · 1 citation · Cited by this paper
  22. Clinical impact of local consolidative therapy in EGFR-mutant metastatic NSCLC: A propensity-matched multicenter analysis · Eun Sun Lee Eun Sun Lee · 2026 · 1 citation · Cited by this paper
  23. Untitled · Cited by this paper

Source: OpenAlex (CC0)